Citius Oncology (CTOR) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed Citius Oncology (CTOR) over the past year, gaining 2.0% versus a loss of 54.6%. PDS Biotechnology is the larger company by market cap ($100.0 million vs $88.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTOR | PDSB |
|---|---|---|
| Share price | $0.8398 | $1.38 |
| Market cap | $88.82M | $100.01M |
| 1-day change | +0.57% | +35.29% |
| YTD return | -16.50% | +32.47% |
| 1-year return | -54.62% | +2.00% |
| 5-year return | — | -91.73% |
| EPS (TTM) | $-0.48 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.25 | $1.55 |
| 52-week low | $0.491 | $0.195 |
| Distance from 52-week high | -62.68% | -10.97% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +376.30% | +262.32% |
| Average volume | 100.32K | 23.24M |
| Shares outstanding | 105.76M | 72.47M |
| Employees | — | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed CTOR by 56.6 percentage points over the past year.
About Citius Oncology
CTOR stock →Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
CTOR vs PDSB FAQ
Which is bigger, Citius Oncology or PDS Biotechnology?
PDS Biotechnology (PDSB) is larger, with a market capitalization of $100.01M compared with $88.82M for Citius Oncology (CTOR).
Which stock has performed better over the past year, CTOR or PDSB?
PDSB returned +2.00% over the past 12 months, compared with -54.62% for CTOR (price return, excluding dividends). Past performance does not predict future results.
Are Citius Oncology and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.